ADRB3 and obesity disorder: Whilst encouraging, the effects of ADRB3 agonists tested so far are considered modest and short lived, partly due to reduced ADRB3 expression and catecholamine resistance in the adipose tissue of individuals with obesity (Valentine et al., 2022).